Companies

Galapagos NV

NASDAQ: GLPG

About Galapagos

Lakefront Biotherapeutics NV (formerly Galapagos NV; Euronext & NASDAQ: LKFT) is a biotechnology company building a clinical-stage portfolio in immunology and inflammation.

The portfolio is anchored by gamgertamig, a BCMAxCD3 T-cell engager being developed for autoimmune diseases. Ongoing Phase 1b studies cover autoimmune cytopenias (ITP and AIHA) and seropositive autoimmune diseases (myositis, Sjögren's disease and pemphigus). Gamgertamig holds FDA Fast Track and Orphan Drug designations and is expected to enter registrational studies in 2027. Partner Keymed runs gamgertamig studies in Greater China.

The company also holds three preclinical autoimmune and inflammatory programs acquired with Ouro Medicines. Gilead holds an opt-in on these programs for a 50/50 profit split.

Current revenue consists mainly of supplying Jyseleca to Alfasigma under a transition agreement, plus limited collaboration revenue from Gilead.

The company is completing the wind-down of its CAR-T cell therapy activities. It sold its next-generation early-stage cell therapy pipeline to Armed Cell Therapeutics and discontinued GLPG3667.

With roughly €2.2 billion in cash and financial investments, Lakefront pursues a business-development model of acquiring and advancing high-quality assets. It also returns capital through share repurchases. The company plans to move its reporting and functional currency to the U.S. dollar. Updated

GLPG Coverage

Frequently Asked Questions

What does Galapagos do?

Lakefront Biotherapeutics NV (formerly Galapagos NV; Euronext & NASDAQ: LKFT) is a biotechnology company building a clinical-stage portfolio in immunology and inflammation. The portfolio is anchored by gamgertamig, a BCMAxCD3 T-cell engager being developed for autoimmune diseases.